Brookline Capital Markets Forecasts Moderna FY2026 Earnings

Moderna, Inc. (NASDAQ:MRNA – Free Report) – Stock analysts at Brookline Capital Markets upped their FY2026 earnings estimates for Moderna in a research note issued on Friday, November 6th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings per share of ($5.45) for the year, up from their prior forecast of ($6.46). Brookline Capital Markets currently has a “Buy” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($5.34) per share. Brookline Capital Markets also issued estimates for Moderna’s Q4 2026 earnings at ($2.87) EPS, FY2027 earnings at ($2.79) EPS and FY2028 earnings at ($0.16) EPS.

Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. The business had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The firm’s quarterly revenue was up 29.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.51) EPS.

A number of other equities research analysts have also commented on MRNA. Barclays raised their price target on Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a research report on Monday, August 24th. Jefferies Financial Group reissued a “hold” rating and set a $150.00 target price (up from $60.00) on shares of Moderna in a research note on Wednesday, August 19th. Morgan Stanley raised their target price on shares of Moderna from $89.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. Citigroup reaffirmed a “sell” rating on shares of Moderna in a research note on Friday, October 23rd. Finally, Piper Sandler reiterated an “overweight” rating and issued a $305.00 price target (up from $230.00) on shares of Moderna in a report on Monday. Six equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $113.75.

Get Our Latest Report on MRNA

Moderna Stock Down 7.0%

NASDAQ:MRNA opened at $231.35 on Wednesday. Moderna has a 1 year low of $22.28 and a 1 year high of $280.80. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. The stock has a 50-day moving average price of $200.18 and a two-hundred day moving average price of $95.52.

Insider Activity at Moderna

In other news, President Stephen Hoge sold 39,145 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the completion of the transaction, the president directly owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. This trade represents a 2.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the sale, the insider owned 74,129 shares in the company, valued at $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Moderna

Several hedge funds have recently modified their holdings of MRNA. Dogwood Wealth Management LLC raised its stake in shares of Moderna by 158.8% during the 3rd quarter. Dogwood Wealth Management LLC now owns 132 shares of the company’s stock worth $25,000 after purchasing an additional 81 shares in the last quarter. Western Pacific Wealth Management LP bought a new position in shares of Moderna in the third quarter valued at $29,000. Allied Private Wealth LLC bought a new position in shares of Moderna in the 2nd quarter valued at about $30,000. CENTRAL TRUST Co raised its holdings in shares of Moderna by 36.5% in the 3rd quarter. CENTRAL TRUST Co now owns 172 shares of the company’s stock valued at $33,000 after purchasing an additional 46 shares during the period. Finally, Next Level Wealth Planning LLC bought a new stake in shares of Moderna in the 3rd quarter valued at about $34,000. Institutional investors own 75.33% of the company’s stock.

Key Moderna News

Investors following MRNA have been watching these news items:

  • Positive Sentiment: The company reported peer-reviewed real-world data on mNEXSPIKE in adults aged 65 and older, based on an analysis of more than 294,000 U.S. veterans. The findings may help support the vaccine’s commercial position. Moderna is also scheduled to join the MSCI World Index in November, potentially broadening its investor visibility. Article: Moderna Index Inclusion and Vaccine Data
  • Neutral Sentiment: Moderna presented an oncology-led growth strategy, including work on its personalized cancer vaccine. That pipeline could become a meaningful source of future growth, but its commercial potential remains uncertain and will take time to establish. Article: Moderna’s Oncology Growth Plan
  • Negative Sentiment: Despite the raised forecast, coverage noted that Moderna’s 2026 revenue outlook may still be below analyst expectations, fueling concern about a potential sales shortfall. That outlook, combined with elevated investment needs, appears to have outweighed the positive updates. Article: Why Moderna Stock Dropped

About Moderna

(Get Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Recommended Stories

Earnings History and Estimates for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.